Answers are grounded in this paper and cite their sources.
Integrating artificial intelligence and machine learning into pharmaceutical R&D is revolutionizing the industry by increasing productivity and improving the effectiveness of drug discovery, development, and healthcare delivery. This review examines the varied applications of artificial intelligence and machine learning in predictive modeling, medication repurposing, lead optimization, and clinical trials. The review emphasizes artificial intelligence's role in regulatory compliance, pharmacovigilance, and customized medicine, while also considering ethical and regulatory issues. Artificial intelligence generative models have advanced structure-based drug design through improved molecular docking and quantitative structure–activity relationship modelling. In clinical trials, artificial intelligence enhances patient recruitment, predicts outcomes, and enables real-time monitoring. Artificial intelligence-driven predictive maintenance, process optimization, and inventory management have increased efficiency in pharmaceutical manufacturing and supply chains. Artificial intelligence has also strengthened personalized medicine by supporting genomic analysis, biomarker identification, and intelligent diagnostics. While artificial intelligence improves treatment outcomes and operational efficiency, it introduces ethical and legal challenges that require transparent and accountable implementation. Future progress will depend on collaborative efforts to ensure responsible use and support the continued evolution of the pharmaceutical industry.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: